SCHEDULE 13G/A

NEWAMSTERDAM PHARMA COMPANY

Ordinary Shares, nominal value EUR0.12 per share · CUSIP: N62509109

Event date: 2025-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares

Unavailable

Percent of class

Unavailable

• VIKING GLOBAL INVESTORS LP

  Shares: 4,203,567 · Class: 3.7%

• Viking Global Opportunities Parent GP LLC

  Shares: 4,203,567 · Class: 3.7%

• Viking Global Opportunities GP LLC

  Shares: 2,817,205 · Class: 2.5%

• Viking Global Opportunities Portfolio GP LLC

  Shares: 2,817,205 · Class: 2.5%

• Viking Global Opportunities Illiquid Investments Sub-Master LP

  Shares: 2,817,205 · Class: 2.5%

• Viking Global Opportunities Drawdown GP LLC

  Shares: 1,386,362 · Class: 1.2%

• Viking Global Opportunities Drawdown Portfolio GP LLC

  Shares: 1,386,362 · Class: 1.2%

• Viking Global Opportunities Drawdown (Aggregator) LP

  Shares: 1,386,362 · Class: 1.2%

• HALVORSEN OLE ANDREAS

  Shares: 4,203,567 · Class: 3.7%

• Ott David C.

  Shares: 4,203,567 · Class: 3.7%

• Shabet Rose Sharon

  Shares: 4,203,567 · Class: 3.7%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.